一种愈创木烷型倍半萜苷单体化合物及其制备方法和用途
By extracting and purifying the sesquiterpene glycoside monomer compound atractylone A from Atractylodes lancea, the problem of the lack of effective drugs for treating type 2 diabetes and inflammation in the existing technology has been solved, and significant hypoglycemic and anti-inflammatory effects have been achieved.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- INST OF BOTANY JIANGSU PROVINCE & CHINESE ACADEMY OF SCI
- Filing Date
- 2022-08-25
- Publication Date
- 2026-07-17
AI Technical Summary
There is a lack of effective natural drug sources in the current technology for the treatment of type 2 diabetes and its associated inflammation, especially drugs that improve insulin sensitivity and lower blood sugar.
A novel sesquiterpene glycoside monomer compound, abilide A, was extracted, isolated, and purified from the fresh rhizomes of Atractylodes lancea for the preparation of hypoglycemic and anti-inflammatory drugs. The preparation was carried out by methods such as water or organic solvent extraction, petroleum ether and ethyl acetate extraction, column chromatography, and macroporous resin adsorption.
A novel natural drug, atractylodes lactone A, has been obtained, which has significant hypoglycemic and anti-inflammatory effects, expanding the drug sources for the treatment of type 2 diabetes and providing better treatment options.
Smart Images
Figure SMS_1 
Figure SMS_2 
Figure QLYQS_1